- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
Home
Microbiology
Antiviral chemical
-
Apoptosis related activator
-
DNA/RNA Synthesis inhibitor
-
Nucleoside Analog/Antimetabolite inhibitor
Acyclovir (Aciclovir)
僅限科研使用
Acyclovir (Aciclovir)
別名: Acycloguanosine, ACV, NSC 645011,BW 248U 中文名稱：阿昔洛韋
Acyclovir (Aciclovir)是一種合成的核苷類似物，有效作用于皰疹病毒。Acyclovir 可在Jurkat白血病細胞中誘導細胞周期紊亂和凋亡。
Acyclovir (Aciclovir) Chemical Structure
CAS: 59277-89-3
產(chǎn)品質(zhì)控
批次：
純度：
99.93%
99.93
Acyclovir (Aciclovir)相關(guān)產(chǎn)品
| 相關(guān)產(chǎn)品 | Moroxydine HCl Aloperine Harringtonine GS-441524 Oleanolic Acid LL-37 acetate NGI-1 U-18666A Aloin B Saikosaponin B2 Lapachol DTNB | 點擊展開 |
|---|---|---|
| 相關(guān)化合物庫 | 抗感染化合物庫 抗生素化合物庫 抗病毒化合物庫 抗寄生蟲藥物庫 腸道微生物代謝物庫 | 點擊展開 |
細胞實驗數(shù)據(jù)示例
| 細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息(PMID) |
|---|---|---|---|---|---|
| african green monkey Vero cells | Function assay | 48 h | Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay, EC50=1.87 μM | ||
| HEL cells | Function assay | 4 days | Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days, EC50=0.2 μM | ||
| African green monkey Vero 76 cells | Cytotoxicity assay | 48-96 h | Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining, CC50=13 μM | ||
| BSC-1 cells | Function assay | Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells, IC50=2.6 μM | |||
| P3HR-1 cells | Function assay | Effective concentration for the inhibition of Epstein-Barr virus EBV-DNA synthesis in human lymphoblastoid P3HR-1 cells, EC50=6.75 μM | |||
| HFF cells | Function assay | Concentration for HSV-1 plaque reduction (VPR) by 50% in HFF cells, EC50=1.1 μM | |||
| HFF cells | Function assay | Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) by 50 % in HFF cells, EC50=2.22 μM | |||
| human embryonic lung cells | Function assay | Antiviral activity was measured as effective concentration required to reduce Varicella Zoster virus (OKA)-induced plaque formation in human embryonic lung cells, EC50=1.1 μM | |||
| HEL cells | Function assay | Compound was tested for anti-viral activity against HSV-1(G) in HEL cells, EC50=1.3 μM | |||
| HEL cell | Function assay | Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in OKA strain HEL cell lines, EC50=4.53 μM | |||
| HSV-2 MS Vero cells | Function assay | Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50%, EC50=6.2 μM | |||
| HSV-1 E-377 Vero cells | Function assay | Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50%, EC50=4.4 μM | |||
| HSV-1 KOS Vero cells | Function assay | Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50%, EC50=2.2 μM | |||
| HeLa cell | Function assay | Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (G) in HeLa cell culture, IC50=0.19 μM | |||
| HEp-2 cells | Function assay | Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (K979) in HEp-2 cells | |||
| HeLa cells | Function assay | Inhibition of HSV-1 DNA synthesis in virus-infected HeLa cells, IC50=1.9 μM | |||
| human HFF cells | Function assay | Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells, EC50=0.04 μM | |||
| human HFF cells | Function assay | Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells, EC50=0.09 μM | |||
| MRC-5 cells | Function assay | Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 2 (HSV-2) in MRC-5 cells, IC50=2.5 μM | |||
| human lung fibroblasts (MRC-5) | Function assay | Compound was tested for antiviral activity against Herpes Simplex virus Type-1(18189) in human lung fibroblasts (MRC-5) | |||
| Raji cells | Function assay | Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells, EC50=2.9 μM | |||
| Vero cells | Function assay | Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells, IC50=1.7 μM | |||
| BSC-1 cells | Function assay | Effective concentration required to inhibit herpes simplex virus 1 in BSC-1 cells in ELISA, EC50=1.5 μM | |||
| HFF cells | Function assay | Effective concentration required to inhibit varicella zoster virus replication in HFF cells, EC50=1.6 μM | |||
| HFF cells | Function assay | Effective concentration required to inhibit herpes simplex virus 1 in HFF cells in cytopathic effect (CPE) assay, EC50=0.9 μM | |||
| Daudi cells | Function assay | Inhibition of EBV replication in Daudi cells by viral capsid antigen-ELISA, EC50=0.33 μM | |||
| WI-38 cell | Function assay | Anti viral activity against VZV(pplla strain) in WI-38 cell monolayers, ID50=4 μM | |||
| HEL cells | Function assay | Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.14 μM | |||
| 點擊查看更多細胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Acyclovir (Aciclovir)是一種合成的核苷類似物，有效作用于皰疹病毒。Acyclovir 可在Jurkat白血病細胞中誘導細胞周期紊亂和凋亡。 | |
|---|---|---|
| 靶點 |
|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06228430 | Not yet recruiting | Healthy Volunteer |
International Bio service |
February 12 2024 | Phase 1 |
| NCT05589688 | Not yet recruiting | Obesity |
University Hospital Toulouse |
January 2024 | Phase 1 |
| NCT06058858 | Not yet recruiting | Cytomegalovirus Infections|Acute Leukemia|B Cell Lymphoma |
Assistance Publique - H?pitaux de Paris |
October 1 2023 | -- |
| NCT05468619 | Recruiting | Herpes Simplex |
National Institute of Allergy and Infectious Diseases (NIAID) |
September 23 2022 | Phase 1 |
|
化學信息&溶解度
| 分子量 | 225.2 | 分子式 | C8H11N5O3 |
| CAS號 | 59277-89-3 | SDF | Download Acyclovir (Aciclovir) SDF |
| Smiles | C1=NC2=C(N1COCCO)N=C(NC2=O)N | ||
| 儲存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 45 mg/mL ( (199.82 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
|
體內(nèi)溶解配方 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 | |||||
實驗計算
動物體內(nèi)配方計算器（澄清溶液）
第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項
